"Antibodies, Neutralizing" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.
Descriptor ID |
D057134
|
MeSH Number(s) |
D12.776.124.486.485.114.244 D12.776.124.790.651.114.244 D12.776.377.715.548.114.244
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Neutralizing".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Neutralizing".
This graph shows the total number of publications written about "Antibodies, Neutralizing" by people in this website by year, and whether "Antibodies, Neutralizing" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2009 | 1 | 0 | 1 |
2010 | 3 | 4 | 7 |
2011 | 3 | 7 | 10 |
2012 | 5 | 1 | 6 |
2013 | 16 | 9 | 25 |
2014 | 14 | 15 | 29 |
2015 | 12 | 9 | 21 |
2016 | 9 | 33 | 42 |
2017 | 153 | 138 | 291 |
2018 | 156 | 143 | 299 |
2019 | 37 | 74 | 111 |
2020 | 169 | 175 | 344 |
2021 | 313 | 324 | 637 |
2022 | 1 | 3 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Antibodies, Neutralizing" by people in Profiles.
-
Early high antibody titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma. Eur Respir J. 2022 02; 59(2).
-
Rapid detection of neutralizing antibodies to SARS-CoV-2 variants in post-vaccination sera. J Mol Cell Biol. 2022 01 29; 13(12):918-920.
-
An easy method for developing fusion enabled SARS-CoV2 virus fusion mimic (SCFM), bypassing the need of Bio Safety Level (BSL) facility. Bioengineered. 2021 12; 12(1):4407-4419.
-
Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies. Emerg Microbes Infect. 2021 Dec; 10(1):1790-1806.
-
Antibodies to SARS-CoV-2 in dogs and cats, USA. Emerg Microbes Infect. 2021 Dec; 10(1):1669-1674.
-
Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19. J Clin Invest. 2021 10 15; 131(20).
-
Attenuated activation of pulmonary immune cells in mRNA-1273-vaccinated hamsters after SARS-CoV-2 infection. J Clin Invest. 2021 10 15; 131(20).
-
[Distribution and infectious characteristics of re-positive cases infected with SARS-CoV-2]. Zhonghua Liu Xing Bing Xue Za Zhi. 2021 Oct 10; 42(10):1750-1756.
-
Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques. Proc Natl Acad Sci U S A. 2021 09 21; 118(38).
-
Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study. J Med Virol. 2022 01; 94(1):279-286.